ASSESSMENT OF RELAPSE OF VISCERAL LEISHMANIASIS AND RISK FACTORS AMONG VISERAL LEISHMANIASIS PATIENTS IN WEST ARMACHIHO, NORTHWEST ETHIOPIA. INSTITUTION BASED RETROSPECTIVE STUDY by MEKONNEN AYELE ( BSC in Clinical Nursing), ZELALEM
 
 
 
 
 
UNIVERSITY OF GONDAR 
COLLEGE OF MEDICINE AND HEALTH SCIENCES 
INSTITUTE OF PUBLIC HELATH 
 
ASSESSMENT OF RELAPSE OF VISCERAL LEISHMANIASIS AND RISK FACTORS 
AMONG VISERAL LEISHMANIASIS PATIENTS IN WEST ARMACHIHO, 
NORTHWEST ETHIOPIA. INSTITUTION BASED RETROSPECTIVE STUDY. 
 
BY: 
ZELALEM MEKONNEN AYELE  ( BSC in Clinical Nursing) 
ADVISORS: 
Mr. MEKURIAW ALEMAYEHU (BSC, MSC) 
Mr. TESFAHUN MELESE (BSC, MPH) 
 
 
A RESEARCH THESIS PAPER TO BE SUBMITTED TO THE INSTITUTE OF PUBLIC 
HEALTH, COLLEGE OF MEDICINE AND HEALTH SCIENCES, UNIVERSITY OF 
GONDAR FOR PARTIAL FULFILMENT OF THE REQUIREMENTS  FOR DEGREE 
OF MASTER OF PUBLIC HEALTH 
 
                                                                                                                       June 2014 
              Gondar, Ethiopia 
                                 
Cl
ick
 to
 bu
y N
OW
!
PD
F-XChange
w
w
w.tracker-softw
are
.c
om Cl
ick
 to
 bu
y N
OW
!
PD
F-XChange
w
w
w.tracker-softw
are
.c
om
 
 
                                          UNIVERSITY OF GONDAR 
COLLEGE OF MEDICINE AND HEALTH SCIENCES 
INSTITUT OF PUBLIC HEALTH 
   
ASSESSMENT OF RELAPSE OF VISCERAL LEISHMANIASIS AND RISK FACTORS 
AMONG VISERAL LEISHMANIASIS PATIENTS IN WEST ARMACHIHO, 
NORTHWEST ETHIOPIA. INSTITUTION BASED RETROSPECTIVE STUDY. 
 
 
 
 By:  Zelalem Mekonnen 
Address: Mobile - +251 918606085 or +251922710283 
Email : zelamekon@gmail.com 
 
Approved by the examined board 
 
 
____________________________                   _______________     
Director, Institute of Public Health                                       Signature 
 
 
Advisors:  
Mr. Mekuriaw Alemayehu (Bsc, Msc)             
Mr. Tesfahun Melese (Bsc, Msc)                 
 
 
 
Examine
Cl
ick
 to
 bu
y N
OW
!
PD
F-XChange
w
w
w.tracker-softw
are
.c
om Cl
ick
 to
 bu
y N
OW
!
PD
F-XChange
w
w
w.tracker-softw
are
.c
om
i | P a g e  
 
                                          Acknowledgement 
 
First  and  for  most,  I  am  very  grateful  to  express  my  sincerely  gratitude  to  my  
advisors Mr.Mekuriaw Alemayehu and Mr.Tesfahun Melese for their immense 
encouragement, guidance and professional comments which were essential for the 
successful completion of this research thesis.  
I would also like to thank University of Gondar, College of Medicine and Health 
sciences, Institute of Public Health for providing the opportunity to do this research 
paper. 
I extend my heartfelt gratitude to the main and mini library staffs for providing the 
necessary reference materials, to the staffs of Gondar University Referral Hospital 
Leishmaniasis Treatment Center and Medicine San Frontiers Holland for their 
valuable inputs for this research paper development.
Cl
ick
 to
 bu
y N
OW
!
PD
F-XChange
w
w
w.tracker-softw
are
.c
om Cl
ick
 to
 bu
y N
OW
!
PD
F-XChange
w
w
w.tracker-softw
are
.c
om
ii | P a g e  
 
                Acronyms and Abbreviations 
 
AIDS   Acquired Immunodeficiency Syndrome 
ART      Antiretroviral Therapy 
CI    Confidence Interval 
CD4   Cluster of Differentiation 
CL                 Cutaneous Leishmaniasis 
DAT   Direct Agglutination Test 
Hgb  Hemoglobin 
HIV   Human Immunodeficiency Virus 
LD   Leishmaniasis Donovani 
LC                 Localized Cutaneous Leishmaniasis 
MSF   Medicines San Frontiers 
PLHIV           People Living with Human Immunodeficiency Virus 
RDT  Rapid Diagnostic Test 
SSG   Sodium stibogluconate 
TB   Tuberculosis 
TOC   Test of Cure 
VCT    Voluntary Counseling and Testing 
VL    Visceral Leishmaniasis 
WHO              World Health Organization 
 
 
 
 
 
 
Cl
ick
 to
 bu
y N
OW
!
PD
F-XChange
w
w
w.tracker-softw
are
.c
om Cl
ick
 to
 bu
y N
OW
!
PD
F-XChange
w
w
w.tracker-softw
are
.c
om
iii | P a g e  
 

Table of Contents
Acknowledgement ........................................................................................................................... i 
Acronyms and Abbreviations ......................................................................................................... ii 
Table of contents……………………………………………………………………………………………………………………………..iii 
List of tables .................................................................................................................................... v 
List of figures.................................................................................................................................. vi 
List of Annex ................................................................................................................................. vii 
Abstract………………………………………………………………………………………………………………………………………….viii 
1.Introduction  ................................................................................................................................. 1 
1.1. Literature review .............................................................................................................. 3 
1.2. Conceptual frame work ................................................................................................... 8 
1.4 Significance of the study ................................................................................................. 9 
2. Objective ................................................................................................................................... 10 
2.1 General objective .......................................................................................................... 10 
2.2 Specific objectives ......................................................................................................... 10 
3. Methods .................................................................................................................................... 11 
3.1   Study design ..................................................................................................................... 11 
3.2 Study area and period .................................................................................................. 11 
3.3 Source and Study Population....................................................................................... 12 
3.3.1 Source Population ....................................................................................................... 12 
3.3.2 Study Population ......................................................................................................... 12 
3.4 Inclusion and Exclusion Criteria ................................................................................... 12 
3.5 Sample size and sampling procedures ....................................................................... 12 
3.6 Variables of the Study ................................................................................................... 13 
3.6.1 Dependent variable: .............................................................................................. 13 
3.6.2 Independent variables: .......................................................................................... 13 
Cl
ick
 to
 bu
y N
OW
!
PD
F-XChange
w
w
w.tracker-softw
are
.c
om Cl
ick
 to
 bu
y N
OW
!
PD
F-XChange
w
w
w.tracker-softw
are
.c
om
iv | P a g e  
 
3.7 Operational definitions .................................................................................................. 13 
3.8 Data Collection Tools and Procedures ........................................................................ 14 
3.9 Data quality control ....................................................................................................... 14 
3.10 Data processing and analysis ...................................................................................... 14 
3.11 Ethical Consideration .................................................................................................... 15 
3.12 Dissemination Of  Results ............................................................................................ 15 
4.Results ...................................................................................................................................... 126 
5. Discussion................................................................................................................................. 27 
6. Limitation and strength of the study ........................................................................................ 29 
7. Conclusions .............................................................................................................................. 30 
8. Recommendations ................................................................................................................... 31 
9 .References................................................................................................................................ 32 
10. Annex ...................................................................................................................................... 34 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cl
ick
 to
 bu
y N
OW
!
PD
F-XChange
w
w
w.tracker-softw
are
.c
om Cl
ick
 to
 bu
y N
OW
!
PD
F-XChange
w
w
w.tracker-softw
are
.c
om
v | P a g e  
 
                                                     List of tables  
 
Table 1: Socio demographic Characteristics among the age groups of Visceral 
leishmaniasis patients in leishmaniasis treatment center at West Armachio, 
Northwest Ethiopia, 2014-------------------------------------------------------------------------16 
Table 2: Clinical and Immunological status among the age groups of visceral 
leishmaniasis patients in leishmaniasis treatment center at West Armachio, 
Northwest Ethiopia, 2014-------------------------------------------------------------------------18 
Table 3: VL relapse incidence density rate among the age groups of visceral 
leishmaniasis patients in leishmaniasis treatment center at West Armachio, 
Northwest Ethiopia, 2014-------------------------------------------------------------------------20 
Table 4: Predictors of VL relapse among the age groups of visceral 
leishmaniasis patients in leishmaniasis treatment center at West Armachio, 
Northwest Ethiopia, 2014-------------------------------------------------------------------------26 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cl
ick
 to
 bu
y N
OW
!
PD
F-XChange
w
w
w.tracker-softw
are
.c
om Cl
ick
 to
 bu
y N
OW
!
PD
F-XChange
w
w
w.tracker-softw
are
.c
om
vi | P a g e  
 
                                                     List of figures 
Figure 1: Conceptual frame work of the study among the age groups of 
Visceral leishmaniasis patients in leishmaniasis treatment center at West 
Armachio, Northwest Ethiopia, 2014-----------------------------------------------------------8 
Figure 2: Relapse of Visceral Leishmaniasis among the age groups of Visceral 
leishmaniasis patients in leishmaniasis treatment center at West Armachio, 
Northwest Ethiopia, 2014 ------------------------------------------------------------------------19 
Figure 3 : Relapse of Cumulative Survival proportion among the age groups of 
Visceral leishmaniasis patients in leishmaniasis treatment center at West 
Armachio, Northwest Ethiopia, 2014 --------------------------------------------------------21 
Figure 4: Relapse of Survival proportion based on Sero status among the age 
groups of Visceral leishmaniasis patients in leishmaniasis treatment center at 
West Armachio, Northwest Ethiopia, 2014--------------------------------------------------22 
Figure 5: Relapse of Survival proportion based on treatment among the age 
groups of Visceral leishmaniasis patients in leishmaniasis treatment center at 
West Armachio, Northwest Ethiopia, 2014--------------------------------------------------23 
Figure 6 :Relapse of Survival proportion based on hemoglobin level among 
the age groups of Visceral leishmaniasis patients in leishmaniasis treatment 
center at West Armachio, Northwest Ethiopia, 2014------------------------------------24
Cl
ick
 to
 bu
y N
OW
!
PD
F-XChange
w
w
w.tracker-softw
are
.c
om Cl
ick
 to
 bu
y N
OW
!
PD
F-XChange
w
w
w.tracker-softw
are
.c
om
vii | P a g e  
 
                                         LIST OF ANNEXES 
Annex 1 Information Sheet - English version………………………………….…...34 
Annex 2 Data collection tools …………………………………………………….......36 
Annex 3 WHO clinical staging criteria……………………………………………….39 
Annex 4 Declaration  ……………………………………………………….………….41 
Cl
ick
 to
 bu
y N
OW
!
PD
F-XChange
w
w
w.tracker-softw
are
.c
om Cl
ick
 to
 bu
y N
OW
!
PD
F-XChange
w
w
w.tracker-softw
are
.c
om
viii | P a g e  
 
                                             ABSTRACT 
Introduction: Leishmaniasis has been associated with poverty and also believed to 
constitute a serious impediment to socioeconomic development. The disease is 
endemic in the environment that ranges from deserts to rain forests in rural and 
urban settings in over 98 countries of the tropics, sub tropics, and southern Europe. 
Objectives: To assess visceral leishmaniasis relapse rate among all visceral 
leishmaniasis patients in leishmaniasis treatment center at West Armachio, 
Northwest Ethiopia, 2014. 
Methods: A five years institution based retrospective follow up study was 
conducted among 1510 VL patients who were enrolled in Leishmaniasis treatment 
center from January, 2009 to December 31, 2013. The information extracted on the 
patient records. The data transfers from excel to SPSS version 20 for analysis. Life 
table was used to estimate the cumulative VL relapse survival and Log rank tests to 
compare relapse survival probability curves between the different categories of the 
explanatory variables. Bivariate and multivariate Cox proportional hazards model 
were used to identify predictors.  
Result: A total of 1676 charts reviewed, out of this 1510 patient records were 
included in the analysis. The median age of the study participant was 24 yrs. And a 
total of 235 VL relapse cases were observed during the follow up period. Hence, the 
overall incidence density of VL relapse was 10 per 10,000 Person months.  
Those who were hemoglobin level >7mg/dl had late probability to develop 
leishmaniasis relapse than Hgb level less than 7 mg/dl with an (AHR 0.69, 95% CI 
0.49, 0.97).and Patients who were taking Ambisone and Ambisone +Meltifocin had 
less likely to develop relapse than a patient taking SSG. (AHR 2.62 CI 95% 1.72, 
3.97) and AHR3.92 CI 95%2.51, 6.12) respectively. 
Discussion: the predictors that were significantly associated with increased risk of 
relapse were HIV/AIDS Sero status, advanced WHO clinical stage and, VL 
treatment, Discharge hemoglobin level and edema. All this predictors had already 
been identified in other studies. 
Conclusion and Recommendation: Leishmaniasis prevention strategies need 
to be strengthened with early diagnosis and treatment as a recommended in national 
guideline. 
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1. Introduction` 
1.1 Statement of the problem 
Leishmaniasis has been associated with poverty and believed to constitute a serious 
impediment to socioeconomic development. The disease is endemic in 
environments that range from deserts to rain forests in rural and urban settings in 
over 98 countries of the tropics, sub tropics, and southern Europe (1).  
 
The Visceral leishmaniasis (VL) and Cutaneous Leishmaniasis (CL) relapse/re-
infection dichotomy is a major concern in patients with HIV/AIDS, who are at risk for 
opportunistic infections. In areas where the diseases are endemic, the rate of re-
infections might be higher than estimated. This could lead physicians to believe that 
treatment for relapsed infection failed. In fact, the patient has a newly acquired 
infection. Therefore, the inability to distinguish relapses from re-infections might be 
an important impediment to the evaluation of leishmaniasis treatment protocols (2). 
 
Changes in the environment (climate change, deforestation and unplanned 
urbanization),  population movements between endemic and non-endemic zones, 
appearance  of  therapy-resistant  strains  and  immune suppression, mainly due to 
malnutrition and co-infection  with  the  human  immunodeficiency  virus  (HIV),are  
among  the  factors  believed  to  contribute  to  emergence and re-emergence of VL. 
(1). 
Visceral Leishmaniasis is predominantly found in the lowlands with varying degrees 
of endemicity. It is estimated that the annual burden of VL ranges from 2,000 to 
4,500 cases of the 350 million people at risk of the disease, globally an estimated 2 
million new cases (1.5 million cases of CL and 500,000 cases of VL) occur annually, 
but only 600,000 cases were officially declared (1, 3). 
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According to the 2012 WHO global Leishmaniasis estimate, Ethiopia is one of the 
ten high burden countries for CL and VL, it is predominantly found in the lowlands 
with varying degrees of endemicity. Population movement, poverty and malnutrition 
associated with presence of the sand fly vector and reservoirs makes the study area 
one of the affected areas by Leishmaniasis, which is a major public Health problem 
(1, 4). 
The number of cases occurring around the world is clearly far higher than officially 
reported, and the number of infections still (4-5 times) higher. The difficulty in 
estimating the case burden is due to several factors: great fluctuations in number of 
cases within short periods of time, focal distribution, and numerous cases 
undiagnosed, as well as, misdiagnosed, not reported often asymptomatic cases. 
Case notification is compulsory in only 30 of the 88 endemic countries (5). 
 
The co-infection of leishmaniasis and HIV is emerging as a new and frightful disease 
and is becoming increasingly frequent. Cases have been reported in 25 countries 
and are currently considered an ominous threat in Spain, Italy, France and Portugal. 
In these countries up to 70% of adult cases of visceral leishmaniasis are associated 
with HIV infection and up to 9% of people with AIDS suffer from newly acquired or 
reactivated visceral leishmaniasis (6). 
Severity of immune suppression, suggests that the patient has not responded 
adequately for treatment. Higher risk of relapse associated with treatment and 
patients with relapse may have died without reaching a treatment center And the 
recurrent attack of visceral leishmaniasis   is a sign of advanced disease and is a 
risk factor for relapse and death. Hence, studying the relapse rate and factors of 
leishmaniasis among PLHIV will have a great importance for the healthcare system 
to making appropriate adjustments as a solution (1). 
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1.1. Literature review 
1.1.1. Relapse 
A recent evidence of study in Nepal suggests that a significant number of patients 
relapse 6–12 months post-treatment with mulitefosine and the relapse rates in  
immune competent patients of between 6.8% to 10.8% at 6 months respectively, 
and  up  to 20.0% at 12 months(7). 
A study showed in India the relapse rates were similar for primary VL and VL 
relapse. CD4 counts ,200 cells/lL at 6 months after ART initiation were predictive of 
subsequent relapse(8). 
Patients who relapsed showed poor CD4 cell count recovery while receiving ART. 
ART was partially protective against VL relapse (HR, 0.46; 95% CI, 0.26–0.82). 
However, 28% of ¿rst VL relapses while receiving ART occurred despite a CD4 cell 
count 1 200 cells/mL; in 5% of VL relapses, the CD4 cell count had been 1 200 
cells/mL for 1 6 months. Factors associated with all-cause mortality among patients 
receiving ART were baseline CD4 cell count ! 100 cells/mL (HR, 3.20; 95% CI, 1.30–
7.87) and VL episodes during follow-up (HR for 1 episode, 4.97 [95% CI, 2.09–
11.86]; HR for 1 2 episodes, 3.22 [95% CI, 1.01–10.23 (6). 
A study in India showed that CD4 cell counts of  .250–300 cells/lL at 6 months after 
VL treatment seemed to be associated with a very low risk of subsequent relapse. 
Four of the eight patients developing VL relapse were patients with previous VL 
relapse and had received VL treatment (conventional amphotericin B) before the 
initiation of liposomal amphotericin B within the program. The mean CD4 cell counts 
at 6, 12, and 24 months after cART initiation were 187 (95% CI,153–221), 234 (95% 
CI, 164–303) and 261 (95% CI, 37–486) cells/lL, respectively (9). 
Male patients had higher odds of relapsing (unadjusted odds ratio [UOR] 1.8; 95% 
CI 1.2–2.6) compared with female patients. Patients aged ,5 years (UOR 3.6; 95% 
CI 1.8–7.2) and 45 years (UOR  2.2;  95%  CI  1.2–1.4)  were  more  likely  to  
relapse  than patients  aged  15  to 30  years.  Factors  not  associated  with relapse 
in the univariate analysis (P- value.0.05)  (10). 
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In South Asia is currently the main focus for VL in the world, accounting for 67% of 
the total leishmaniasis disease burden.  In  2005  Bangladesh  reported  7,000  
cases,  India  re-ported  32,800,  and  Nepal  reported  3,000, . from 2001 to 2005, 
16,210 cases of VL were reported in Brazil, and 315 (2%) patients were co-infected 
with HIV Of the co-infected patients, 78% were male, and the median age was 38 
years (86% of patients were in the 20- to 49-year age group); 56.3% of the HIV 
infections were attributed to heterosexual transmission, and 53% and 29% of the 
cases were reported from the northeastern and southeastern regions, respectively.  
The  clinical  forms  found  among  co infected  cases are 43% MCL, 37% VL, and 
20% CL (9). 
A study conducted in Sudan revealed 18 (15.1%) relapsed within 6 months of 
treatment; 63 (52.9%) within 6–12 months; and 38 (31.9%) 12 months after 
treatment. A Higher odds of relapse compared with size 0 (odds ratio (OR) = 4.40 
(95% CI 1.74–11.08), P = 0.002).17-days SSG/PM was associated with 2-fold higher 
odds of relapse (OR = 2.26 (1.46–3.51), P, 0.001) compared with 30-day SSG 
monotherapy. Test-of-cure  of data  were  available  for  only  4.2%  (7/166)  of 
relapse  patients who had a previous  treatment  record vs. 5.4% (431/7,924)  of  
patients  with  no  record  of  subsequent  relapse (P = 0.6). None of the final test-of-
cure results for relapse patients, and only 3/431 of the test-of-cure results for 
patients with no record of subsequent relapse were positive (10). 
A study conducted in Ethiopia showed that test for cure was not routinely performed 
on all patients and therefore relapse and cure rate could not be established with 
certainty. As the patients did not receive secondary prophylaxis, many relapsed; the 
probability of relapse at 12 months was estimated to be about 70%.Baseline CD4 + 
cell count! 100 cells/mL, tuberculosis co-infection, and previous VL episodes were all 
risk factors for VL relapse. Among patients who received ART, CD4+ cell count 
reconstitution was blunted among those with multiple relapses of VL, compared with 
patients who did not have a VL relapse. A patient with baseline CD4 + cell count! 
100 cells/mL and 3 previous VL episodes would have a 56% chance of relapsing 
within 1 year. Such patients might then be eligible for secondary prophylaxis (e.g., 
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with pentamidine). It is not yet clear after what VL disease–free interval or at what 
CD4+cell count level patients are free of signi¿cant risk of VL relapse (6). 
A study showed in Ethiopia VL relapse was more common among HIV-positive 
patients (40.5%) than among HIV-negative patients (10.6%). Among HIV-positive 
patients, relapse patients had larger spleens and were more malnourished 
compared with primary VL patients. rescue  treatment  of  HIV-positive  patients  with  
Ambisome treatment failure increased the overall cure rate from 59.5% to 82.6%, 
but mortality in patients retreated with SSG was high (15.5%), often due to SSG 
toxicity (11). 
A study showed in Tigray showed that The median age of the 791 cases of visceral 
leishmaniasis was 25 years (10 months to 77 years). More than three-quarters of the 
cohort were aged between 15 and 45 years. The male to female ratio was 11:1; 
females were younger than males, with 42% of the females (27/64) younger than15 
compared to 9% of the males (68/722, P < 0.001 (12). 
A study showed in Humera the adjusted hazard ratios for the effects of ART, 
baseline CD4 + cell count 100 cells/mL, and previous episodes of VL on the primary 
and secondary outcomes. ART had a protective effect on single or multiple relapses 
of VL. A patient with baseline CD4 + cell count 100 cells/mL and previous VL 
episodes would have a 56% chance of relapsing within 1 year (13). 
The study con¿rms that patients with HIV » VL co-infection in Ethiopia had poorer 
response rates to anti-leishmaniasis treatment and increased mortality. Patients with 
HIV–VL co-infection were signi¿cantly less likely to have a positive outcome than 
HIV-negative patients (68.5% vs. 94.5%, P < 0.001). The presence of TB and sepsis 
syndrome also remained signi¿cant in the multivariate analysis as independent 
factors in HIV co-infected patients with VL (AOR 4.52, 95% CI 1.47–13.92 and 9.06, 
95% CI 2.16–37.97, respectively)In a retrospective comparative study of 73 HIV-
positive and 39 HIV-negative Spanish patients with VL, 90% of HIV-negative 
patients responded to treatment compared to only 54.8% of HIV-positive 
patients(14). 
Another study conducted in India showed that male patients had higher odds of 
relapsing (unadjusted odds ratio (UOR) of 1.8; 95% CI 1.2-2.6) compared with 
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female patients. Patients aged, 5 years (UOR 3.6;95% CI 1.8-7.2) and 45 years 
(UOR 2.2;95% CI 1.2-1.4) were more likely to relapse than patients aged 15 to 30 
years. The same study showed that CD4+ cell percentage and absolute count 
measured in the second VL relapse were found to be relatively low (22% and 450/ 
ȝm3, respectively) (22% and 450/ȝm3, respectively). However, even in PLHIV with 
CD4+ cell counts reaching 250 to 300/ȝm3 the risk of relapse seems to be low (15). 
    
WHO guide lines revealed that multiple episodes of relapsing VL in an older patient. 
Beyond the known decreased capacity of cytotoxic responses during senescence, 
no other immune-suppressing factor was identified in our case. CD4+ cell 
percentage and absolute count measured in the second VL relapse were found to be 
relatively low (22% and 450/ȝm, respectively). However, even in human 
immunodeficiency  virus  cases(PLHIV) with  CD4+  cell  counts reaching 250 to 
300/ ȝm the risk of relapse to the best of our knowledge, there are very few reports 
of relapsing VL in the immune competent in the literature (15) (10). 
 
Another study also showed that patients who exhibited a decrease in spleen size of 
0.5 cm/day by the time of discharge appeared to have higher odds of relapse (1.7; 
95%  CI  1.1–2.5)  compared  with  those  who  exhibited  a decrease in spleen size 
of .0.5 cm/day. No other clinical factors were significantly associated with risk of 
relapse. Notably, nutritional status, spleen size and Hb level upon admission, and 
duration of treatment were not predictive of relapse. Relapse  rates  in  immune 
competent  patients  between  6.8%  to  10.8%  at  6  months  respectively,  and  up  
to20.0% at 12 months in Nepal  (10). 
A study conducted in Sudan revealed that the larger  spleen  size  upon admission 
and at the time of discharge were strongly associated with relapse, as was treatment 
with short-course combination treatment(17 days sodium stibogluconate 
/paromomycin vs. 30 days sodium stibogluconate). Age, sex, nutritional status, 
mobility, and treatment complications were  significantly associated with relapse(2).       
The study confirms that patients with HIV/VL co-infection in Ethiopia had poorer 
response rates to anti Leishmaniasis treatment and increased mortality. positive 
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outcome was achieved in 94.5% of HIV negative patients compared to only 68.5% of 
co-infected patients. In a retrospective comparative study of 73 HIV positive and 39 
HIV negative Spanish patients with VL, 90 % of HIV negative responded to 
treatment compared to only 54.8 % of HIV positive patients. There was also a three 
times higher mortality rate in HIV positive than HIV negative patients(17.5% vs. 
5.4%)  (16). 
 
A study In Ethiopia   Splenomegaly on admission may indicate severity of illness, 
parasite burden, and degree of immune suppression. The prevalence of triple co-
infection (VL, HIV, and tuberculosis) among HIV-positive VL patients in our study 
was 29.7%,  similar  to  that  observed  in  another  Ethiopian  study A total of 130 » 
137 (94.9%) of HIV-negative and 65 » 69  (94.2%)  of  HIV-positive patients with 
haemoglobin measurements were anaemic. Total white cell and platelet counts were 
available for 118 and 105 HIV-negative patients and 51 and 39 HIV-positive patients. 
Thrombocytopenia was more commonly seen in HIV-negative than co-infected 
patients (90.5% v 76.9%, OR = 2.85, 95% CI 1.06–7.67, P = 0.038 (17). 
 
Another study in shows that there was no difference in initial cure rate between the 
miltefosine group (88.3%; 95% CI, 84.0%–91.7%)  and  the  SSG  group  (87.6%; 
83.2%–91.2%) (P-value 0.90). However, initial treatment failure with survival was 
more Frequent in the miltefosine group (7.9% in the miltefosine group vs. 0.7% in 
the SSG group; OR, 12.4; ), whereas mor- P ! .0001 mortality was lower in the 
miltefosine group (2.1% in the miltefosine group vs. 9.7% in the SSG group; OR, 
0.20; ). P-value .0002. the independent risk factors for death were determined to be 
receiving SSG rather than miltefosine (OR,6.53;  95%  CI,  2.53–16.89),  being  HIV-
infected  or  having an unknown HIV status (OR, 3.54; 95% CI, 1.25–10.06), and 
vomiting (OR, 2.97; 95% CI, 1.28–6.87). Other risk factors for death (age, body 
mass index, hemoglobin level, diarrhea, and inability to walk unaided) were 
interdependent  (18). 
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1.2. Conceptual frame work  
Distal factors                                         proximal factors 
 
 
 
 
 
 
 
 
 
 
Figure. 1: Conceptual frame work for the occurrence of relapse of leishmaniasis 
among leishmaniasis/HIV co-infected on in leishmaniasis treatment center at MSF 
leishmaniasis treatment center in west Armachio district, January 2009 to December 
2013.   
Socio demography  
Age  
Sex  
Residence  
 
 
 
 
Leishmaniasis 
relapse rate 
 
Clinical characteristics  
WHO clinical stage  
CD4 count  
Hgb level  
Leishmaniasis treatment history  
Nutritional status   
Spleen size 
 
         Treatment related  
Leishmaniasis treatment regimen 
Initial ART regimen  
Regimen change  
Adherence  
Drug resistance 
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1.4 Significance of the study 
Leishmaniasis is the commonest cause of morbidity and mortality among PLHIV. It is 
also special in HIV infected patients because it increases the occurrence of relapse, 
other opportunistic infections and it occurs at various WHO clinical stage of HIV 
infection and it is fatal. In addition to this, unless we prevent in advance by 
identifying the potential risk factors, the anti-leishmaniasis treatment takes a long 
time unlike other opportunistic infection treatment which create a burden for those 
who are on HAART.   
There are lots of challenges associated with VL treatment. Challenges may be 
related to the preparation of the available drugs, treatment choice and availability of 
the drugs .The drugs widely used are injectables, It is painful and very expensive, 
with high toxicity and less efficacy for HIV co-infected VL patients.  
Therefore, this study will determine the factors that are responsible for relapse of 
Leishmaniasis diagnosis and treatment. And it will provide an input and directions to 
governmental policy makers and non-governmental organizations on Leishmaniasis 
treatment, prevention and control strategy. This study will be used as a base line for 
further study.  
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2. Objective 
2.1 General objective 
¾ To assess visceral leishmaniasis relapse rate among all visceral 
leishmaniasis patients in leishmaniasis treatment center at West Armachio, 
Northwest Ethiopia, 2014. 
2.2 Specific objectives 
¾ To determine the relapse rate of visceral leishmaniasis occurrence among 
visceral leishmaniasis patients. 
¾ To identify the risk factors of relapse of visceral leishmaniasis occurrence 
among visceral leishmaniasis patients.   
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3. Methods 
3.1   Study design 
A five years institution based retrospective follow up study was conducted. 
3.2 Study area and period 
The study was conducted at West Armachio Leishmaniasis Treatment Center from 
March 25/ 2014 to April 15/ 2014. This Leishmaniasis treatment center is found in 
west Armachio Woreda, Its  run by international nongovernmental organization of 
Medicines sans frontiers’ located in North Gondar administrative zone, Amhara 
National Regional state, which is found at about 727 km Northwest of Addis Ababa 
(the capital city of Ethiopia).  
According to the 2007 population and housing census report, the total population 
size of west Armachio Woreda was estimated which serves residents 35,486 people, 
of which female 15,969 and 19,517 male (population data from Woreda health office 
2012) and Migrant workers, an average 300,000 less than 2% females and Settlers 
about 33,976 (22,341 male, 11,640 female). 
The treatment center of leishmaniasis has one project coordinator, two expatriate 
medical doctors and one Ethiopian doctor for providing leishmaniasis and ART 
services, 4 Health officers , 4 BSc Nurse. And 13 Diploma nurses, 1 data clerks, 
1porter, 2 janitors,3 case manager and 8 adherence supporters (people living with 
HIV). The treatment center uses standardized monitoring and evaluation tools and 
the data collection and management process is well controlled and supported by 
electronic data back-up and processing. 
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3.3 Source and Study Population 
3.3.1 Source Population 
All patients who have got Visceral Leishmaniasis in West Armachio Woreda were 
the source population. 
3.3.2 Study Population 
All patients who have visceral leishmaniasis relapse enrolled to leishmaniasis 
treatment center in West Armachio Woreda from January 2009 to December 2013 
were the study population. 
3.4 Inclusion and Exclusion Criteria 
3.4.1 Inclusion:  
All charts of visceral leishmaniasis patients, who enrolled in the leishmaniasis 
treatment center from January 2009 to December 2013. 
3.4.2 Exclusion:  
Charts with incomplete documentation of patients history were excluded. 
3.5 Sample size and sampling procedures 
All charts of visceral leishmaniasis patients,who were registered from January 2009 
to December 2013 at the leishmaniasis treatment center in West Armachio Woreda 
Medicines San Frontiers (MSF) project were included in the study. 
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3.6 Variables of the Study 
3.6.1 Dependent variable: 
Relapse of Visceral leishmaniasis  
3.6.2 Independent variables: 
 Socio-demographic characteristics:  Age, Sex, Residence and Address.  
 Clinical characteristics: WHO clinical Stage of HIV,CD4+ counts, 
Hemoglobin level (Hgb) at admission and at discharge time, spleen size at 
admission and discharge time, Nutritional status, Sero status, Tb co-infection, 
 Follow-up clinical and treatment related characteristics: initial 
leishmaniasis regimen and duration, prior history of leishmaniasis, functional 
status, and treatment defaulter. 
 
3.7 Operational definitions 
Relapse: The reoccurrence of Visceral leishmaniasis in patients with HIV co-
infection or no HIV co-infection after a full treatment regimen which is tested positive 
by spleenic aspiration, or bone marrow aspiration and identified by signs and 
symptoms.  
Defaulter: A patient who fails to finish treatment of visceral leishmaniasis because 
of hepatotoxicity, cardio-toxicity or by other causes like co-infection of TB and 
concomitant infections.  
Splenomeglay: A patient with an abnormal increment of the spleen size. 
Anemia: The level of red blood cell count or hemoglobin (Hgb) of patients < 7 (1, 19) 
Migrant - who travels seasonally, or has been to the site for less than two years.  
Settler - who have moved to the place and lived for more than two years.  
Resident - who has been there for generations or (lived more than ten years). 
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3.8 Data Collection Tools and Procedures 
The available information on the patient records were first observed and appropriate 
data extraction cheek list was prepared in English. Then the data was extracted by 
two nurses who are working in the health center using the prepared data collection 
cheek list. One data clerk also was supporting them by identifying the charts/ 
electronics. Charts/electronics were retrieved using the patients’   registration 
numbers that are found in data base in the electronic system established by MSF-
Holland. 
3.9 Data quality control 
Quality of data were maintained by recruiting data collectors who took ART and 
leishmaniasis diagnosis and treatment trainings. The data collectors were given 
intensive training for one day before the data collection on the objective of the study 
and how to retrieve data for this study purpose using the data extraction format. 
They were briefed on the definition of variables on the cheek list and registration 
charts. The retrieval process was closely monitored by the principal investigator 
throughout the data collection period. Completed forms were checked regularly for 
completeness of the information and any gaps identified were immediately 
communicated to the data collectors.  
3.10 Data processing and analysis 
After checking for completeness, the data were entered to excel then exported to 
SPSS version 20 for analysis. Data were entered by the principal investigator and 
clean before analysis.   
Summary statistics was carried out to describe the demographics, base line and 
follow up data. Relapse density rate (RDR) was calculated for the entire study 
period. Life table was used to estimate the cumulative survival of relapse of 
leishmaniasis. Log rank test was used to compare survival probabilities between the 
different categories of the explanatory variables.  
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Both bivariate and multivariate Cox proportional hazard model was used to identify 
the predictors. Variables with p value <0.2 in the bivariate analysis were entered into 
the multivariate proportional hazard model. Ninety five percent (95%) confidence 
interval of hazard ratio was computed and variables having p value < 0.05 in the 
multivariate Cox proportional hazards model was considered as significantly and 
independently associated with the dependent variable. The necessary assumptions 
of Cox proportional hazard model were checked by using schoenfield residuals test 
and graphically. 
3.11 Ethical Consideration 
Ethical clearance was obtained from the research review committee of the Institute 
of Public Health, University of Gondar. Permission of a written letter was obtained 
from Medicine San Frontiers medical team leaders and management teams of 
leishmaniasis treatment center. And oral permission also was obtained from data 
clerk focal person to use the secondary data for the purpose of this study. The name 
or any other identifying information were not recorded on the cheek list and all 
information taken from the chart/electronics was kept strictly confidential and in a 
safe place. The information retrieved was used only for the study purpose.  
3.12 Dissemination of Results 
The result was summated as partial fulfillment of the degree of Master of Public 
Health in epidemiology and biostatistics to the institute of Public Health, College of 
Medicine and Health Sciences, University of Gondar.  
It will be also disseminated to Amhara regional Health bureau, North Gondar Health 
Department and nongovernmental organizations who are specially working on 
Leishmaniasis, HIV/AIDS and Malnutrition (medicine sans frontiers’). The result will 
be also presented at University of Gondar annual research conference, and other 
conferences and workshops. Moreover, the result will be sent for publication at 
scientific National or international journals. 
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4. Results: 
4.1 Socio-demographic characteristics of Leishmaniasis patients 
A total of 1676 records of Leishmaniasis pts who were enrolled from January 1, 
2009 to December 31, 2013 were reviewed. of these 166 (10 %) were not included 
in the analysis due to missing of records. Among 1510 (90%) patients remaining in 
the analysis, 1450 (96 %) of Leishmaniasis patient were male. Almost half of 
699(46.3%) of them were in the age group of 15-24 years and 530(35%) 25-34 
years. The median age of the study participants was 24yrs.  
Participants In west Armachio district 810 (53.6%) of the patients were residents 
while 564 (37.4 %) of them were migrant workers. 
Table 1: Socio demographic characteristics of leishmaniasis patients at MSF 
leishmaniasis treatment center, January 1, 2009 to December 31, 2013.   
Characteristics         Number              Percent 
Age     
<=14yrs 108 7.2 
15-24yrs 699 46.3 
25-34yrs 530 35.1 
>=35yrs 173 11.5 
Sex     
Male  1450 96.0 
Female 60 4.0 
Residence      
Migrant worker 564 37.4 
Resident 810 53.6 
Settlers 136 9.0 
Ethnicity     
Amhara 1342 88.9 
Tigray 144 9.5 
Oromia 16 1.1 
Afar 8 .5 
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4.2 Clinical and immunological status of the study participants  
Total eligible leishmaniasis patients had 1510 (90%), out of this 336 (22.2 %) of 
them were HIV/AIDS co-infected and 1174 (77.7%) were Non HIV/AIDS Primary 
kalazar patients, among those co-infected patients 186 (55.4%) of them were 
relapsed and 150 (44.6%) weren’t relapsed. Among 1174 (77.7%) of PKA 49(4.1%) 
of them were relapsed the rest 1125(95.8%) weren’t relapsed.  
Out of 1510 leishmaniasis patients 128 (8.4%) of them were Tb co-infected, 
55(42.9%) and 73(57%) of them were leishmaniasis relapse and non relapse 
respectively. In this study the discharge hemoglobin had highly significant which 
was <7mg/dl is 1328 (87.9%). 
  
 
 
 
 
 
 
 
 
 
 
Figure : Clinical and immunological status of the study participants at MSF 
leishmaniasis treatment center in west Armachio district, January 1, 2009 to 
December 31, 2013.   
All leishmaniasis patients (1510) 
Primary kalazar (PKA) 1174 (77.7%) 
 
Leishmaniasis and HIV/IADS 
co-infected pts 336 (22.2%) 
Non relapse PKA pts 
1125(95.85) 
 
PKA Relapse 49(4.1%) 
 
Non relapsed HIV/AIDS 
co-infected pts 150 
(44.6%) 
 
Relapse  of Visceral 
Leishmaniasis 
HIV/AIDS co-infected 
186 (55.4%) 
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Table 2: Clinical and immunological status of leishmaniasis patients  and co-
infected of HIV/AIDS at  MSF leishmaniasis treatment center from January, 
2009- December, 2013.   
 Characteristics Number       Percent   
                         
Edema     
Yes 165 10.9 
No 1345 89.1 
Admition spleen size     
spleen size < =3 cm 1136 75.2 
spleen size > 3cm 374 24.8 
Admition Hgb     
Hgb <= 7 g/dl 1435 95.0 
Hgb >7g/dl 75 5.0 
Discharge spleen size     
spleen size < =3 cm 1444 95.6 
spleen size > 3 cm 66 4.4 
Discharge Hgb level     
Hgb <=7g/dl 1328 87.9 
Hgb >7g/dl 182 12.1 
Tb co infection     
Positive 128 8.5 
Negative 1382 91.5 
Sero status     
Positive 336 22.3 
Negative 1174 77.7 
   
CD4 count     
<200 156 46.4 
>=200 56 16.6 
Treatment type     
SSG 919 60.9 
Ambisone 419 27.7 
Ambisone + Meltifocin 172 11.4 
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4.3 Leishmaniasis Relapse Incidence density rate 
Leishmaniasis relapse rate was classified based on socio-demographic and clinical 
characteristics. One thousand five hundred ten study individuals were followed for 
different periods for five years. Within the follow up period, 1275 (84.4%) new 
Leishmaniasis cases were observed. Hence, the overall Relapse rate was 235 
(15.6%). The Study participants were followed for a minimum of 3 month and a 
maximum of 60 months.  
The Incidence density rate of relapse among the age group of 15-24 and 25-34 was  
4.3/10,000 person month and 15.5/10,000 person month respectively. And The 
Incidence density of discharge hgb < = 7mg/dl and hgb > 7mg/dl was 23.5 /10,000 
person month and 8.7/10,000 person month respectively. The incidence density 
rate of Sero status of the study participant was 51.6/10,000n person month and 
2.5/10,000 person month respectively. Total incidence density rate of relapse was 
10/10,000 person month. 
 
Figure 2:  Relapse of leishmaniasis among the age groups at MSF leishmaniasis 
treatment center in west Armachio district, January 1, 2009 to December 31, 2013.   
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Table 3: Relapse incidence density rate stratified by socio-demographic and clinical 
characteristics of Leishmaniasis at MSF leishmaniasis treatment center from January, 
2009- December, 2013.   
Characteristics Total PM Relapse case     Relapse IDR/10,000 
     Sex         
Male  1450 222960 229 10.2 
Female 60 10899 6 5.5 
Age         
<=14yrs 108 19722.0 5 2.5 
15-24yrs 699 112351.5 48 4.2 
25-34yrs 502 73056.0 113 15.5 
>=35yrs 201 28729.5 69 24 
Residence          
Migrant worker 564 85312.5 108 12.6 
Resident 810 118278.0 121 10.2 
Settlers 136 30268.5 6 1.98 
Edema         
Yes 165 22704.0 55 24.2 
No 1345 211155.0 80 3.7 
Addmition spleen size         
spleen size <= 3 cm 1265 198303.0 205 10.3 
spleen size > 3 cm 245 35556.0 30 8.4 
Discharge spleen size         
spleen size < =3 cm 1462 226614.0 231 10.1 
spleen size > 3 cm 48 7245.0 4 5.5 
Addmition Hgb         
Hgb < 7mg/dl 465 60895.5 64 10.5 
Hgb >= 7mg/dl 1045 172963.5 171 9.8 
Discharge Hgb level         
Hgb <=7mg/dl 166 20356.5 48 23.5 
Hgb > 7mg/dl 1344 213502.5 187 8.7 
Tb co infection         
positive 128 16957.5 55 32.4 
negative 1382 216901.5 180 8.29 
Sero status         
positive 336 35820.0 185 51.6 
negative 1174 198039.0 50 2.5 
Treatment type         
SSG 808 159754.5 36 2.2 
Ambisone 419 65968.5 83 12.5 
Ambisone + Meltifocin 283 8136.0 116 14.5 
PM (person month)     
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The cumulative probability of Leishmaniasis relapse of survival at the end of 3 
month was 0.98; that of surviving at the end of 6 month was 0.90; that of surviving 
at the end of 9 month was 0.87 and that of surviving at the end of first year (12) 
month was 0.85.and that of surviving at the end of 24 month was 0.83; and that of 
surviving at the end of 45 month was 0.82; that of surviving at the end of 60 month 
was 0.82. The median survival time from enrolment to leishmaniasis relapse 
occurrence is 60 month.  
 
Figure 3: The cumulative survival proportion for leishmaniasis and HIV/AIDS Co-
infected on MSF-H leishmaniasis treatment center at west Armachio, January 2009 
to December 2013. 
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4.4 Factors of Leishmaniasis relapse occurrence 
Log rank (Mantel-Cox) test of equality of survival for the different categories of 
explanatory variables, treatment type, Sero status, CD4 count and Discharge hgb 
level and Oedema were significantly associated with Relapse of leishmaniasis.  The 
mean survival time of Relapse for those who had Sero status was 30.1and 
57.4months respectively. The difference was significant at p < 0.001.    
P-value <0.001
 
Figure 4: The relapse proportion based on Sero status among All leishmaniasis on 
MSF-H leishmaniasis treatment center at west Armachio, January 2009 to 
December, 2013. 
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The mean survival time of Relapse for those who had taking treatment of SSG, 
Ambisone and Ambisome+ Meltifocin was 57.5, 48.4 and 21.5 months respectively. 
The difference was significant at p < 0.001.  
P-value <0.001
 
Figure 5: The relapse proportion based on Clinical treatment among All 
leishmaniasis and HIV/AIDS co-infected on MSF-H leishmaniasis treatment center 
at west Armachio, Jan 2009 to December, 2013. 
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The mean survival time of Relapse for those who had Discharge haemoglobin 
level<7mg/dl and >7mg/dl was 42.0, and 51.8 months respectively. The difference 
was significant at p < 0.001. 
 
 
Figure 5: The relapse proportion based on Discharge hemoglobin level among All 
Visceral leishmaniasis and HIV/AIDS co-infected at MSF-H leishmaniasis treatment 
center at west Armachio, January 2009 to December, 2013. 
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4.5 Multivariate analyses of factors associated with visceral 
leishmaniasis relapse in HIV-positive and HIV-negative patients. 
Findings from bivariate Cox-regression analysis showed that Age, residence 
Edema, Hemoglobin level, Tb co-infection, Sero status, baseline CD4 cell count, 
Baseline WHO clinical stage III and stage IV and drug used had association with 
Relapse of leishmaniasis with free survival time among people living with HIV/AIDS. 
In the multivariate Cox-regression analysis, Edema, Sero status, CD4 cell count 
and WHO clinical stage, hemoglobin level, Treatment remained statistically 
significant predictors of time to Leishmaniasis relapse occurrence. 
A patient with CD4 cell count greater than 200 cell/ul is 1.26 times late probably  to 
have leishmaniasis relapse at any time than a patient with a CD4 cell count less 
than 200 cell/ul (AHR= 1.26,95% CI 0.85,1.87) respectively. 
Those who were hemoglobin level >7mg/dl had late probablity to develop 
leishmaniasis relapse than hgb level less than 7 mg/dl. (AHR 0.69, 95% CI 0.49, 
0.97). 
Patients who were taking Ambisone and Ambisone +Meltifocin had less likely to 
develop relapse than a patient taking SSG. (AHR 2.62 CI 95% 1.72, 3.97) and 
AHR3.92 CI 95%2.51, 6.12) respectively. 
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Table 4: Clinical status of Leishmaniasis and HIV/AIDS co-infected patients on 
Leishmaniasis treatment center at MSF-Holland in west Armachio district January 
1/2009 to December 31, 2013.   
     
                 Relapse of Kalazar   
   Characteristics  Relapse        Non   
Relapse 
 CHR(95%CI) AHR(95%CI) 
      Age          
<=14yrs 5 103                   1   
15-24yrs 48 651  1.54 (0.62, 3.87)   
25-34yrs 113 389  5.19 (2.12,12.73)   
>=35yrs 69 132   8.29 (3.34 , 20.55)   
Residence           
Migrant worker 108 456                1   
Resident 121 689  0.79 (0.61 , 1.03 )   
Settlers 6 130  0.20 ( 0.09 ,0.46)   
Discharge Hgb          
Hgb < =7mg/dl 48 118                1  1 
Hgb >7mg/dl 187 1157     0.43 ( 0.32 ,0.59 ) 0.69 (0.49 ,0.97) 
Tb co infection          
Positive 76 56                 1   
Negative 1264 182         0.28  (0.21 , 0.38 )   
Sero status          
Positive 185 151                1 1 
Negative 50 1124          0.64 (0.05,0.09) 0.22(0.14, 0.37) 
Clinical stage of HIV/AIDS        
 
  
stage II 12 16                1 1 
stage III 29 12         2.87(1.36 ,6.08) 1.64(0.99 ,2.71) 
Stage IV 121 94          2.11(1.07,4.15) 1.51 (1.03,2.21) 
CD4 count          
<200 156 0                1 1 
> 200 32 24           5.13 (3.53 , 7.46) 1.26 (0.85 ,1.87) 
Treatment type          
SSG 36 772                 1 1 
Ambisone 83 336  5.17 ( 3.49 ,7.65 ) 2.62 (1.72 ,3.97) 
Ambisone + Meltifocin 116 167  17.79 (12.19 , 25.99  3.92 (2.51 ,6.12) 
Admition edema          
Yes 55 110                1 1 
No 180 1165  0.39(0.29 ,0.53) 0.67(0.49,0.93) 
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5. Discussion 
 
As seen from this study the predictors that were significantly associated with 
increased risk of relapse were HIV/AIDS Sero status, VL treatment, Discharge 
hemoglobin level and edema. All this predictors had already been identified in other 
studies. 
This study revealed that treatment of VL had highly significant. Its inline with a study 
in Sudan, it suggests that a significant number of patients relapse 6–12 months 
post-treatment with mulitefosine and the relapse rates in  immune competent 
patients of between 6.8% to 10.8% at 6 months respectively, and  up  to 20.0% at 
12 months(7). In addition to this, other studies in ethiopia revealed that OR 6.53 
95% CI 2.53,16.89) The reasons of these was all  treatment type is toxic and painful 
and takes a longer period of time.  
This study shows that 90% of the study participants were enrolled in the 
leishmaniasis treatment center and 15.6 % of them were VL relapsed. It is in line 
with Nepal, the Relapse  rates  in  immune competent  patients  between  6.8%  to  
10.8%  at  6  months  respectively,  and  up  to 20.0% at 12 months in Nepal (10)  
This research work has also found that patients with baseline CD4 < 200 cells/ µl 
had 1.26 AHR(95% CI (0.85 ,1.87) times higher risk of developing relapse  as 
compared to CD4baseline>200 cells/ µl. It is in line with In India. This could be due 
to the fact that patients became bed reddened or ambulatory as result of affected 
by many infectious diseases when their CD4 cell count is low.  Baseline CD4 cell 
count of < 200 cells/ µl was a very strong and independent risk factor associated 
with a higher risk of VL relapse in patients enrolled to Leishmaniasis treatment 
center(10). 
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As seen in this study the spleen size is no significant for relapse of Visceral 
leishmaniasis ,but a study revealed in Sudan, the larger  spleen  size  upon 
admission and at the time of discharge were strongly associated with relapse, as 
was treatment with a short-course combination treatment  (17days  sodium 
stibogluconate /paromomycin  vs 30 days sodium stibogluconate). Age, sex, 
nutritional status, mobility, and treatment complications were significantly 
associated with relapse (2). 
This research work has also found that patients with VL relapse had a risk of 
developing TB as compared to working functional status. Other studies in  Ethiopia 
It has significant association with TB. The presence of TB and sepsis syndrome 
also remained signi¿cant in the multivariate analysis as independent factors in HIV 
co-infected patients with VL (AOR 4.52, 95% CI 1.47–13.92 and 9.06, 95% CI 
2.16–37.97, respectively (14) 
As revealed from this study Discharge hemoglobin level has highly significant for VL 
relapse. It is in lower than a study in Ethiopia. A total of 130 » 137 (94.9%) of HIV-
negative and 69 (94.2%) of HIV-positive patients with hemoglobin measurements 
were anemic. Total white cell and platelet counts were available for 118 and 105 
HIV-negative patients and 51 and 39 HIV-positive patients. Thrombocytopenia was 
more commonly seen in HIV-negative than co-infected patients (90.5% v 76.9%, 
OR = 2.85, 95% CI 1.06–7.67, P = 0.038.The reasons for lowered discharged Hgb 
level was because of the pathogenesis leishmaniasis infectivity of the vital organs 
(6). 
As seen from this study HIV positive VL patients has significantly associated with 
relapse of visceral leishmaniasis, it is in line with other studies in Nepal, Sudan, and 
Ethiopia. 
This study also showed that Edema has significantly associated with relapse of 
Visceral leishmaniasis. but other studies they didn’t identified it. 
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6. Limitation and strength of the study 
 
Limitations: 
Since it was based on secondary data some of the important predicators which had 
a significant association with Leishmaniasis relapse occurrence with other studies 
like body mass index were not included in the analysis due to incomplete 
registration of the charts. 
Those study subjects whose charts lost weren’t included in the study which may 
undermine the result if it is related with Leishmaniasis. 
Strength: 
The study was conducted for a long follow up (five years) period which enabled us 
to know the long term impact of   leishmaniasis relapse at the treatment center.  
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7. Conclusions 
 
Relapse rate of leishmaniasis was high among people living with HIV/AIDS 
especially in the first year of enrollment to the treatment center.  
Relapse of leishmaniasis was effectively treated by Ambisone and meltefocin than 
SSG treatment on HIV/AIDS co-infected pts.    
Advanced WHO clinical stage, and low CD4 (<200cell/ul) count, discharge 
hemoglobin level found to be the independent predictor of relapse leishmaniasis 
occurrence.  
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8. Recommendations  
 
¾ To governmental and nongovernmental organizations 
• Leishmaniasis and HIV/AIDS collaborative long term surveillance program 
should be strengthening at leishmaniasis endemic areas.   
• Leishmaniasis prevention strategies need to be strengthened with early 
diagnosis and treatment as a recommended in national guideline   
¾ To Health care providers 
• Close follow-up and screening of patient especially with in the first year of 
enrollment to the treatment center. 
• It would be better to give special attention for ambulatory or Bed redden, 
WHO clinical stage III or IV and people with low (<200 cell/ul) CD4 cell count 
to diagnose, prevent and treat leishmaniasis early.  
¾ For the patients 
• Early seek of health care; enrolled to the treatment center and taking ART 
have great importance to reduce the risk of Relapse.  
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1. Annex 
Annex 1 - Information Sheet 
Title of the Research Project:  Assessment of Visceral leishmaniasis relapse 
among al leishmaniasis patients and HIV co infected patients in west Armachio 
Woreda North west Ethiopia, retrospective study of risk factors. 
Name of Investigator: Zelalem Mekonnen (Bsc in clinical Nurse) 
Name of the Organization: University of Gondar College of Medicine and Health 
Sciences, Institute of Public Health. 
Name of the Sponsor: self sponsor. 
Introduction: this information sheet is prepared for North Gondar zonal BOH, west 
Armachio Woreda BOH and leishmaniasis treatment project center team leaders 
Medicine sans frontiers’ (MSF) coordinating office. The aim of the form is to make 
the above concerned office clear about the purpose of research, data collection 
procedures and get permission to conduct the research.  
Purpose of the Research Project: To Evaluate the level of Visceral leishmaniasis 
relapse rate among all leishmaniasis patients and HIV co infected patients  in 
leishmaniasis treatment center at west Armachio, Northwest Ethiopia, retrospective 
study of risk factors, from January, 2009 to December, 2013. 
Procedure: In order to achieve the above objective, information which is necessary 
for the study will be taken from leishmaniasis treatment center medical record follow 
up forms.  
Risk and /or Discomfort: The study will be conduct by taking appropriate 
information from medical chart, it will not inflict any harm on the patients. The name 
or any other identifying information will not be record on the questionnaire and all 
information taken from the chart will be kept strictly confidential and in a safe place. 
The information retrieved will only be used for the study purpose. 
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Benefits: the research have no direct benefit for one whose document/ record is 
included in this research. But the indirect benefit of the research for the participant 
and other clients in the program is clear. This is because if program planners are 
preparing predict a plan, there is a benefit for clients in the program of getting 
appropriate care and treatment services.  Of all, the research work has a 
paramount direct benefit for health care planners and managers, especially for 
those on HIV/leishmaniasis co- infected collaborative program planning and 
management. 
Confidentiality: to reassure confidentiality the data on the chart will be collect by 
those Nurses who are working in the leishmaniasis treatment project center and 
information will be collect without the name of the clients. The information collect 
from this research project will be kept confidential and will be store in a file. In 
addition, it will not be revealed to anyone except the investigator and it will be kept 
in key and locked system with computer pass ward.  
Person to contact: This research project will be review and approve by the 
institutional review board of College of Medicine and Health Science, University of 
Gondar. If you want to know more information, you can contact the committee 
through the address below. If you have any question you can contact any of the 
following individuals (Investigator and Advisors) and you may ask at any time you 
want. 
1. Zelalem Mekonnen, University of Gondar, College of Medicine and Health 
Science, Department of public Health: principal investigator  
Cell phone: +251- 922- 71-02-83 
E-mail: zelamekon@gmail.com 
2. Mekuriaw  Alemayehu  (Bsc, MSc) University of Gondar, College of Medicine 
and Health Science, institute of Public Health:Environmental and 
Occupational Health and safety: Advisor  Cell phone: +251-09 20 51 00 50E-
mail: mekuriaw04@gmail.com 
3. Tesfahun Melese (MPH)University of Gondar, College of Medicine and Health Science, 
institute of Public Health: Advis 
Cell phone: +251- 918- 77-98-20 E-mail: tesfahunmelese@gmail.com 
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Annex 2- Data collection tool 
Questionnaire prepared for collection of data on the patients ART or/and pre ART 
medical registration book/chart to assess the relapse of Visceral leishmaniasis 
among people living with HIV attending in HIV care clinic at Medicine sans frontiers’ 
treatment center. 
Code No._________________________________ 
S. 
N. 
Part I: Socio demographic characteristics Skip to Qn 
101 Date of enrolment                /                /                    
/DD/MM/YY 
 
102 Age at enrolment  year  
103 Sex 1. Male                               2. Female   
104 Marital status 1. Never married/ single  
2. Married  
3. Separated 
4.  divorced 
5. Widowed/er 
6. Others (specify)--------------------- 
 
105 Level of education   1. No education  
2. Primary (Grade 1- 8) 
3. Secondary (Grade 9-10) 
4. Preparatory (Grade 11-12) 
5. Diploma level 
6. Degree level 
7. Not recorded 
 
106 Religion 1. Orthodox  
2. Muslim  
3. Protestant  
4. Catholic 
5. Others (specify) ---------------------- 
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107 Occupation          ____________________________  
108 Address 1. Urban         2.  Rural          3. Not 
recorded 
 
 
 
 
 Part II: Past Leishmaniasis treatment& other history  
201  Did the patient had past 
leishmaniasis treatment 
history?  
1. Yes                3. Not recorded 
2. No 
 
202 Is the treatment completed? 1. Yes                  2.  No   
203 Number of house hold ______________persons  
204 Height  _____________Cm  
205 Weight _____________Cm  
 Part III: HIV  care/ ART follow up  
301 Date confirmed HIV+ // (DD/MM/YY)  
302 ART Eligible date  // (DD/MM/YY)  
303  Eligible criteria  1. CD4 cell count                  3. Both 
2. WHO clinical stage           4. Not 
recorded  
 
 
304 Date ART started // (DD/MM/YY)  
305 When was it changed //(DD/MM/YY)& month ---------  
306 New regiment    
307 Reason for switch  1. Side effects          3. leishmaniasis 
2. Pregnancy           4. Others -----------
-------- 
 
308 Current status of VL pts 1.Alive 
2.Dead 
3.Relapsed 
4.Defoulted 
5.Drug resistance 
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309 CD4 count ------------------------ cells  
310 Stage of HIV/AIDS 1. Satge I  
 2. Stage II 
 3. Stage III 
 4. Stage IV 
311 Admition spleen size -----------------------cm  
312 Discharge spleen size -----------------------cm  
313 Admition hemoglobin level -----------------------g/dl  
314 Discharge hemoglobin level -----------------------g/dl  
315 Did the patient develop 
leishmaniasis after  
treatment  
1. Yes           2. No   
316  When was it developed?               /                 /                DD/MM/YY  
317 During what was it 
developed? 
1. Pre ART     2. ART   
318 What type of leishmaniasis 
was it? 
Visceral leishmaniasis 
Cutaneous leishmaniasis 
 
319 Which type of drug used for 
primary VL treatment? 
Ambisonepentamidin 
SSG                   paranomicin 
Meltifocin 
 
320 Which type of drug used 
after relapse of VL? 
Ambisonepentamidin 
SSG                   paranomicin 
Meltifocin 
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Annex 3-WHO HIV clinical staging criteria 
1. WHO Staging System for HIV Infection and Disease in Adults and 
Adolescents 
 
2. Detailed description of the clinical stages of HIV/AIDS 
Clinical stage 1:  a person with confirmed HIV infection who isasymptomatic 
and/or Persistent generalized lymphadenopathy (PGL) 
Clinical stage 2: Apersonwith confirmed HIV infection and having: 
x Moderate unexplained weight loss (<10% of presumed or measured body 
weight) 
x Recurrent respiratory tract infections (RTIs, sinusitis, bronchitis, otitis media, 
pharyngitis) 
x Herpes zoster 
x Angular cheilitis 
x Recurrent oral ulcerations 
x Popular pruritic eruptions 
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x Seborrhoeic dermatitis x Fungal nail infections of fingers 
Clinical stage 3: Conditions where a presumptive diagnosis can be made on the  
 basis of clinical signs or simple investigations: 
x Severe weight loss (>10% of presumed or measured body weight) 
x Unexplained chronic diarrhoea for longer than one month 
x Unexplained persistent fever (intermittent or constant for longer than one 
month) 
x Oral candidiasis 
x Oral hairy leukoplakia 
x Pulmonary tuberculosis (TB) diagnosed in last two years 
x Severe presumed bacterial infections (e.g. pneumonia, empyema, 
pyomyositis, bone or joint infection, meningitis, bacteraemia) 
x Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis 
Clinical stage 4: Conditions where a presumptive diagnosis can be made on the 
basis of clinical signs or simple investigations: 
Cl
ick
 to
 bu
y N
OW
!
PD
F-XChange
w
w
w.tracker-softw
are
.c
om Cl
ick
 to
 bu
y N
OW
!
PD
F-XChange
w
w
w.tracker-softw
are
.c
om
1 | P a g e  
 
x HIV wasting syndrome 
x Pneumocystis Carinii  pneumonia 
x Recurrent severe or radiological  bacterial pneumonia 
x Chronic herpes simplex infection (orolabial, genital or anorectal of   more than 
one month’s duration) 
x Oesophageal candidiasis 
x Extra pulmonary TB 
x Kaposi’s sarcoma 
x Central nervous system (CNS)      toxoplasmosis 
x HIV encephalopathy 
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